That theory is exactly what makes this question so compelling for researchers exploring peptide-based fat loss strategies
Patients generally return to daily activities in 10 days
Generally appropriate for: Adults with a BMI over 27 who want to lose weight People who have struggled with appetite control Those looking for sustainable, medically-supervised weight loss Generally not appropriate if: Pregnant or breastfeeding individuals People with a personal or family history of thyroid cancer Those with multiple endocrine neoplasia syndrome (MEN 2) Individuals with diabetic retinopathy (certain eye conditions) Common side effects: Nausea (especially at the start, usually improves) Loss of appetite (expected and therapeutic) Mild constipation or diarrhea Occasional headache or dizziness These typically subside as your body adjusts Individual results vary
This experiment is part of the cooperation project MitoCow funded by the German Research Foundation (DFG, 202989534)
Understanding GLP-1 Inhibitors By now, most of us are familiar with GLP-1 medications like Ozempic (semaglutide), Wegovy (semaglutide), and Monjourno (tirzepatide), commonly used to treat type 2 diabetes and now weight loss
The metabolic adaptations that defend higher body weight do not disappear just because weight has been lost